Kinins and microglial responses in bipolar disorder: A neuroinflammation hypothesis

Biological Chemistry

Volumn 397, Issue 4, 2016, Pages 283-296

  Naaldijk, Yahaira M ^b   Bittencourt, Maria C ^c   Sack, Ulrich ^b   Ulrich, Henning ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

bipolar disorder; inflammation; kallikreinkinin system; microglia

Indexed keywords

BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; KININ; LITHIUM; NEUROTROPHIC FACTOR; VALPROIC ACID; LITHIUM DERIVATIVE;

BIPOLAR DISORDER; CELL ACTIVATION; COMORBIDITY; DISEASE COURSE; DSM-5; GENE EXPRESSION; HUMAN; ICD-10-CM; IMMUNOMODULATION; INTRACELLULAR SIGNALING; KALLIKREIN KININ SYSTEM; LIFE EXPECTANCY; MENTAL PATIENT; MICROGLIA; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; INFLAMMATION; METABOLISM; PATHOLOGY;

BIPOLAR DISORDER; HUMANS; INFLAMMATION; KININS; LITHIUM COMPOUNDS; MICROGLIA; NEUROIMMUNOMODULATION;

EID: 84960981914     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2015-0257     Document Type: Review

References (163)

1. Adomeit, A., Graness, A., Gross, S., Seedorf, K., Wetzker, R., and Liebmann, C. (1999). Bradykinin B(2) receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires dual signaling via both protein kinase C pathway and epidermal growth factor receptor transactivation. Mol. Cell. Biol. 19, 5289-5297.
2. American Psychiatric Association (2013). American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (Arlington, VA: American Psychiatric Publishing).
3. Appell, K.C. and Barefoot, D.S. (1989). Neurotransmitter release from bradykinin-stimulated PC12 cells. Stimulation of cytosolic calcium and neurotransmitter release. Biochem. J. 263, 11-18.
4. Arts, B., Jabben, N., Krabbendam, L., and van Os, J. (2008). Metaanalyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol. Med. 38, 771-785.
5. Austin, C.E., Faussner, A., Robinson, H.E., Chakravarty, S., Kyle, D.J., Bathon, J.M., and Proud, D. (1997). Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways. J. Biol. Chem. 272, 11420-11425.
6. Austinat, M., Braeuninger, S., Pesquero, J.B., Brede, M., Bader, M., Stoll, G., Renné, T., and Kleinschnitz, C. (2009). Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 40, 285-293.
7. Barnett, J.H. and Smoller, J.W. (2009). The genetics of bipolar disorder. Neuroscience 164, 331-343.
8. Bassett, D. (2015). A literature review of heart rate variability in depressive and bipolar disorders. Aust. N. Z. J. Psychiatry. doi:10.1177/0004867415622689 [Epub ahead of print]
9. Belmaker, R.H. (2004). Bipolar disorder. N. Engl. J. Med. 351, 476-486.
10. Ben-Neriah, Y. and Karin, M. (2011). Inflammation meets cancer, with NF-B as the matchmaker. Nat. Immunol. 12, 715-723.
11. Benedetti, F., Bernasconi, A., Lorenzi, C., Pontiggia, A., Serretti, A., Colombo, C., and Smeraldi, E. (2004). A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci. Lett. 355, 37-40.
12. Benes, F.M., Matzilevich, D., Burke, R.E., and Walsh, J. (2006). The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol. Psychiatry 11, 241-251.
13. Berk, M, Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., Yücel, M., Gama, C.S., Dodd, S., Dean, B., Magalhães, P.V., et al. (2011). Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35, 804-817.
14. Bhoola, K.D., Figueroa, C.D., and Worthy, K. (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1-80.
15. Brietzke, E., Stertz, L., Fernandes, B.S., Kauer-Sant'anna, M., Mascarenhas, M., Escosteguy Vargas, A., Chies, J.A., and Kapczinski, F. (2009). Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 116, 214-217.
16. Burch, R.M. and Kniss, D.A. (1988). Modulation of receptormediated signal transduction by diacylglycerol mimetics in astrocytes. Cell. Mol. Neurobiol. 8, 251-257.
17. Campbell, D.J. (2001). The kallikrein-kinin system in humans. Clin. Exp. Pharmacol. Physiol. 28, 1060-1065.
18. Catena-Dell'Osso, M., Rotella, F., Dell'Osso, A., Fagiolini, A., and Marazziti, D. (2013). Inflammation, serotonin and major depression. Curr. Drug. Targets 14, 571-577.
19. Chang, C.K., Hayes, R.D., Perera, G., Broadbent, M.T., Fernandes, A.C., Lee, W.E., Hotopf, M., and Stewart, R. (2011). Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One 6, e19590.
20. Chen, P.H., Gildengers, A.G., Lee, C.H., Chen, M.L., Kuo, C.J., and Tsai, S.Y. (2015). High serum sodium level in affective episode associated with coronary heart disease in old adults with bipolar disorder. Int. J. Psychiatry. Med. 50, 422-433.
21. Chiang, W.C., Chien, C.T., Lin, W.W., Lin, S.L., Chen, Y.M., Lai, C.F., Wu, K.D., Chao, J., and Tsai, T.J. (2006). Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic. Biol. Med. 41, 1304-1314.
22. Collier, D.A., Stöber, G., Li, T., Heils, A., Catalano, M., Di Bella, D., Arranz, M.J., Murray, R.M., Vallada, H.P., Bengel, D., et al. (1996). A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol. Psychiatry 1, 453-460.
23. Cotter, D., Mackay, D., Landau, S., Kerwin, R., and Everall, I. (2001). Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch. Gen. Psychiatry 58, 545-553.
24. Couture, R., Harrisson, M., Vianna, R.M., and Cloutier, F. (2001). Kinin receptors in pain and inflammation. Eur. J. Pharmacol. 429, 161-176.
25. De Dios, C., Ezquiaga, E., Agud, J.L., Vieta, E., Soler, B., and García-López, A. (2012). Subthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients. J. Affect. Disord. 143, 160-165.
26. Dell'Aglio, J.C., Basso, L.A., Argimon, I.I., and Arteche, A. (2013). Systematic review of the prevalence of bipolar disorder and bipolar spectrum disorders in population-based studies. Trends Psychiatry Psychother. 35, 99-105.
27. Dikic, I., Tokiwa, G., Lev, S., Courtneidge, S.A., and Schlessinger, J. (1996). A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 383, 547-550.
28. Ding-Zhou, L., Margaill, I., Palmier, B., Pruneau, D., Plotkine, M., and Marchand-Verrecchia, C. (2003). LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia. Br. J. Pharmacol. 139, 1539-1547.
29. Ekdahl, C.T. (2012). Microglial activation - tuning and pruning adult neurogenesis. Front. Pharmacol. 3, 41.
30. Elhaik, E. and Zandi, P. (2015). Dysregulation of the NF-B pathway as a potential inducer of bipolar disorder. J. Psychiatr. Res. 70, 18-27.
31. Fountoulakis, K.N. (2012). Introduction-bipolar illness: current understanding and future perspectives. CNS Neurosci. Ther. 18, 193.
32. Fountoulakis, K.N., Vieta, E., Sanchez-Moreno, J., Kaprinis, S.G., Goikolea, J.M., and Kaprinis, G.S. (2005). Treatment guidelines for bipolar disorder: a critical review. J. Affect. Disord. 86, 1-10.
33. Fountoulakis, K.N., Gonda, X., Koufaki, I., Hyphantis, T., and Cloninger, C.R. (2016). The role of temperament in the etiopathogenesis of bipolar spectrum illness. Harv. Rev. Psychiatry 24, 36-52.
34. Frick, L.R., Williams, K., and Pittenger, C. (2013). Microglial dysregulation in psychiatric disease. Clin. Dev. Immunol. 2013, 608654.
35. Gabra, B.H. and Sirois, P. (2002). Role of bradykinin B(1) receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice. Eur. J. Pharmacol. 457, 115-124.
36. Gimpl, G., Walz, W., Ohlemeyer, C., and Kettenmann, H. (1992). Bradykinin receptors in cultured astrocytes from neonatal rat brain are linked to physiological responses. Neurosci. Lett. 144, 139-142.
37. Golias, C., Charalabopoulos, A., Stagikas, D., Charalabopoulos, K., and Batistatou, A. (2007). The kinin system-bradykinin: biological effects and clinical implications. Multiple role of the kinin system-bradykinin. Hippokratia 11, 124-128.
38. Gould, T.D. (2006). Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. Expert. Opin. Ther. Targets 10, 377-392.
39. Gould, T.D., Picchini, A.M., Einat, H., and Manji, H.K. (2006). Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets 7, 1399-1409.
40. Gratacòs, M., Costas, J., de Cid, R., Bayés, M., González, J.R., Baca-García, E., de Diego, Y., Fernández-Aranda, F., Fernández-Piqueras, J., Guitart, M., et al. (2009). Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B, 808-816.
41. Gray, J.D. and McEwen, B.S. (2013). Lithium's role in neural plasticity and its implications for mood disorders. Acta Psychiatr. Scand. 128, 347-361.
42. Green, H.F. and Nolan, Y.M. (2012). GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia. Neurochem. Int. 61, 666-671.
43. Gröger, M., Lebesgue, D., Pruneau, D., Relton, J., Kim, S.W., Nussberger, J., and Plesnila, N. (2005). Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 25, 978-989.
44. Hamdani, N., Doukhan, R., Kurtlucan, O., Tamouza, R., and Leboyer, M. (2013). Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications. Curr. Psychiatry Rep. 15, 387.
45. Hashimoto, K., Sawa, A., and Iyo, M. (2007). Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62, 1310-1316.
46. Hilty, D.M., Leamon, M.H., Lim, R.F., Kelly, R.H., and Hales, R.E. (2006). A review of bipolar disorder in adults. Psychiatry (Edgmont) 3, 43-55.
47. Himmerich, H. (2011). [Appropriateness of antidepressant treatment for mild depression]. M.M.W. Fortschr. Med. 153, 31-33.
48. Himmerich, H., Fischer, J., Bauer, K., Kirkby, K.C., Sack, U., and Krügel, U. (2013). Stress-induced cytokine changes in rats. Eur. Cytokine Netw. 24, 97-103.
49. Himmerich, H., Bartsch, S., Hamer, H., Mergl, R., Schönherr, J., Petersein, C., Munzer, A., Kirkby, K.C., Bauer, K., and Sack, U. (2014). Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-Cd40-stimulated blood in vitro. Oxid. Med. Cell. Longev. 2014, 806162.
50. Hope, S., Dieset, I., Agartz, I., Steen, N.E., Ueland, T., Melle, I., Aukrust, P., and Andreassen, O.A. (2011). Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J. Psychiatr. Res. 45, 1608-1616.
51. Huang, C.D., Tliba, O., Panettieri, R.A., and Amrani, Y. (2003). Bradykinin induces interleukin-6 production in human airway smooth muscle cells: modulation by Th2 cytokines and dexamethasone. Am. J. Respir. Cell. Mol. Biol. 28, 330-338.
52. Huang, Z., Han, Z., Ye, B., Dai, Z., Shan, P., Lu, Z., Dai, K., Wang, C., and Huang, W. (2015). Berberine alleviates cardiac ischemia/reperfusion injury by inhibiting excessive autophagy in cardiomyocytes. Eur. J. Pharmacol. 762, 1-10.
53. Huisman, C., Kok, P., Schmaal, L., and Verhoog, P. (2008). Bradykinin: a microglia attractant in vivo? J. Neurosci. 28, 3531-3532.
54. Hübers, A., Voytovych, H., Heidegger, T., Müller-Dahlhaus, F., and Ziemann, U. (2014). Acute effects of lithium on excitability of human motor cortex. Clin. Neurophysiol. 125, 2240-2246.
55. Ifuku, M., Färber, K., Okuno, Y., Yamakawa, Y., Miyamoto, T., Nolte, C., Merrino, V.F., Kita, S., Iwamoto, T., Komuro, I., et al. (2007). Bradykinin-induced microglial migration mediated by B1-bradykinin receptors depends on Ca2+ influx via reverse-mode activity of the Na+/Ca2+ exchanger. J. Neurosci. 27, 13065-13073.
56. Imeri, L. and Opp, M.R. (2009). How (and why) the immune system makes us sleep. Nat. Rev. Neurosci. 10, 199-210.
57. Iwahashi K,. Nishizawa, D., Narita, S., Numajiri, M., Murayama, O., Yoshihara, E., Onozawa, Y., Nagahori, K., Fukamauchi, F., Ikeda, K., et al. (2014). Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders. Clin. Neuropharmacol. 37, 108-110.
58. Jakobsson, J., Bjerke, M., Sahebi, S., Isgren, A., Ekman, C.J., Sellgren, C., Olsson, B., Zetterberg, H., Blennow, K., Pålsson, E., et al. (2015). Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J. Psychiatry Neurosci. 40, 250-258.
59. Jann, M.W. (2014). Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. Am. Health Drug Benefits 7, 489-499.
60. Judd, L.L., Schettler, P.J., Akiskal, H.S., Coryell, W., Leon, A.C., Maser, J.D., and Solomon, D.A. (2008). Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch. Gen. Psychiatry 65, 386-394.
61. Kapczinski, F., Frey, B.N., Andreazza, A.C., Kauer-Sant'Anna, M., Cunha, A.B., and Post, R.M. (2008). Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev. Bras. Psiquiatr. 30, 243-245.
62. Kim, Y.K., Jung, H.G., Myint, A.M., Kim, H., and Park, S.H. (2007). Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 104, 91-95.
63. Kohman, R.A. and Rhodes, J.S. (2013). Neurogenesis, inflammation and behavior. Brain Behav. Immun. 27, 22-32.
64. Koo, J.W. and Duman, R.S. (2008). IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. USA 105, 751-756.
65. Kraft, A.D. and Harry, G.J. (2011). Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int. J. Environ. Res. Public Health 8, 2980-3018.
66. Krügel, U., Fischer, J., Radicke, S., Sack, U., and Himmerich, H. (2013). Antidepressant effects of TNF-α blockade in an animal model of depression. J. Psychiatr. Res. 47, 611-616.
67. Kunz, M., Gama, C.S., Andreazza, A.C., Salvador, M., Ceresér, K.M., Gomes, F.A., Belmonte-de-Abreu, P.S., Berk, M., and Kapczinski, F. (2008). Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1677-1681.
68. Lappas, M., Permezel, M., Georgiou, H.M., and Rice, G.E. (2002). Nuclear factor kappa B regulation of proinflammatory cytokines in human gestational tissues in vitro. Biol. Reprod. 67, 668-673.
69. Lawrence, T. (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1, a001651.
70. Lawson, L.J., Perry, V.H., and Gordon, S. (1992). Turnover of resident microglia in the normal adult mouse brain. Neuroscience 48, 405-415.
71. Lempérière, T. (2001). [Brief history of the development of valproate in bipolar disorders]. Encephale 27, 365-372.
72. Lim, C.S., Baldessarini, R.J., Vieta, E., Yucel, M., Bora, E., and Sim, K. (2013). Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci. Biobehav. Rev. 37, 418-435.
73. Lull, M.E. and Block, M.L. (2010). Microglial activation and chronic neurodegeneration. Neurotherapeutics 7, 354-365.
74. Machado-Vieira, R., Ibrahim, L., and Zarate, C.A. (2011). Histone deacetylases and mood disorders: epigenetic programming in geneenvironment interactions. CNS Neurosci. Ther. 17, 699-704.
75. Maes, M., Bosmans, E., Calabrese, J., Smith, R., and Meltzer, H.Y. (1995). Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29, 141-152.
76. Maletic, V. and Raison, C. (2014). Integrated neurobiology of bipolar disorder. Front. Psychiatry 5, 98.
77. Marceau, F. and Regoli, D. (2004). Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev. Drug Discov. 3, 845-852.
78. Marceau, F., Hess, J.F., and Bachvarov, D.R. (1998). The B1 receptors for kinins. Pharmacol. Rev. 50, 357-386.
79. Marney, A.M., Ma, J., Luther, J.M., Ikizler, T.A., and Brown NJ. (2009). Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. J. Am. Soc. Nephrol. 20, 2246-2252.
80. Martins, A.H., Resende, R.R., Majumder, P., Faria, M., Casarini, D.E., Tárnok, A., Colli, W., Pesquero, J.B., and Ulrich, H. (2005). Neuronal differentiation of P19 embryonal carcinoma cells modulates kinin B2 receptor gene expression and function. J. Biol. Chem. 280, 19576-19586.
81. Martins, A.H., Alves, J.M., Trujillo, C.A., Schwindt, T.T., Barnabé, G.F., Motta, F.L., Guimaraes, A.O., Casarini, D.E., Mello, L.E., Pesquero, J.B., et al. (2008). Kinin-B2 receptor expression and activity during differentiation of embryonic rat neurospheres. Cytometry A. 73, 361-368.
82. Martins, A.H., Alves, J.M., Perez, D., Carrasco, M., Torres-Rivera, W., Eterović, V.A., Ferchmin, P.A., and Ulrich, H. (2012). Kinin-B2 receptor mediated neuroprotection after NMDA excitotoxicity is reversed in the presence of kinin-B1 receptor agonists. PLoS One 7, e30755.
83. 2+ signaling in single cultured vascular smooth muscle cells. Mol. Pharmacol. 50, 128-139.
84. McGowan, P.O. and Kato, T. (2008). Epigenetics in mood disorders. Environ. Health Prev. Med. 13, 16-24.
85. McIntyre, R.S., Konarski, J.Z., and Yatham, L.N. (2004). Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum. Psychopharmacol. 19, 369-386.
86. Meneton, P., Bloch-Faure, M., Hagege, A.A., Ruetten, H., Huang, W., Bergaya, S., Ceiler, D., Gehring, D., Martins, I., Salmon, G., et al. (2001). Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc. Natl. Acad. Sci. USA 98, 2634-2639.
87. Miller, A.H., Maletic, V., and Raison, C.L. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry. 65, 732-741.
88. Miyamoto, A., Ishiguro, S., and Nishio, A. (1999). Stimulation of bradykinin B2-receptors on endothelial cells induces relaxation and contraction in porcine basilar artery in vitro. Br. J. Pharmacol. 128, 241-247.
89. Mondelli, A., Dazzan, P., and Pariante, C.M. (2015). Immune abnormalities across psychiatric disorders: clinical relevance. B. J. Psych. Advances 21, 150-156.
90. Monfrim, X., Gazal, M., De Leon, P.B., Quevedo, L., Souza, L.D., Jansen, K., Oses, J.P., Pinheiro, R.T., Silva, R.A., Lara, D.R., et al. (2014). Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1β? Bipolar Disord. 16, 741-747.
91. Moorhead, T.W., McKirdy, J., Sussmann, J.E., Hall, J., Lawrie, S.M., Johnstone, E.C., and McIntosh, A.M. (2007). Progressive gray matter loss in patients with bipolar disorder. Biol. Psychiatry 62, 894-900.
92. Moreau, M.E., Garbacki, N., Molinaro, G., Brown, N.J., Marceau, F., and Adam, A. (2005). The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 99, 6-38.
93. Moreno, R.A., Moreno, D.H., Soares, M.B., and Ratzke, R. (2004). [Anticonvulsants and antipsychotics in the treatment of bipolar disorder]. Rev. Bras. Psiquiatr. 26 (Suppl 3), 37-43.
94. Munkholm, K., Braüner, J.V., Kessing, L.V., and Vinberg, M. (2013). Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J. Psychiatr. Res. 47, 1119-1133.
95. Muzina, D.J., Elhaj, O., Gajwani, P., Gao, K., and Calabrese, J.R. (2005). Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta. Psychiatr. Scand. Suppl. 426, 21-28.
96. Nascimento, I.C., Glaser, T., Nery, A.A., Pillat, M.M., Pesquero, J.B., and Ulrich, H. (2015). Kinin-B1 and B2 receptor activity in proliferation and neural phenotype determination of mouse embryonic stem cells. Cytometry A. 87, 989-1000.
97. Negraes, P.D., Trujillo, C.A., Pillat, M.M., Teng, Y.D., and Ulrich, H. (2015). Roles of kinins in the nervous system. Cell Transplant. 24, 613-623.
98. Nelveg-Kristensen, K.E., Busk Madsen, M., Torp-Pedersen, C., Køber, L., Egfjord, M., Berg Rasmussen, H., and Riis Hansen, P. (2015). Pharmacogenetic risk stratification in angiotensin-converting enzyme inhibitor-treated patients with congestive heart failure: a retrospective cohort study. PLoS One 10, e0144195.
99. Ng, F., Berk, M., Dean, O., and Bush, A.I. (2008). Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 11, 851-876.
100. Noda, M., Kariura, Y., Amano, T., Manago, Y., Nishikawa, K., Aoki, S., and Wada, K. (2003). Expression and function of bradykinin receptors in microglia. Life Sci. 72, 1573-1581.
101. Noda, M., Kariura, Y., Amano, T., Manago, Y., Nishikawa, K., Aoki, S., and Wada, K. (2004). Kinin receptors in cultured rat microglia. Neurochem. Int. 45, 437-442.
102. Noda, M., Sasaki, K., Ifuku, M., and Wada, K. (2007a). Multifunctional effects of bradykinin on glial cells in relation to potential anti-inflammatory effects. Neurochem. Int. 51, 185-191.
103. Noda, M., Kariura, Y., Pannasch, U., Nishikawa, K., Wang, L., Seike, T., Ifuku, M., Kosai, Y., Wang, B., Nolte, C., et al. (2007b). Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J. Neurochem. 101, 397-410.
104. O'Brien, S.M., Scully, P., Scott, L.V., and Dinan, T.G. (2006). Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 90, 263-267.
105. Ongür, D., Drevets, W.C., and Price, J.L. (1998). Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. USA 95, 13290-13295.
106. Ortiz-Domínguez, A., Hernández, M.E., Berlanga, C., Gutiérrez-Mora, D., Moreno, J., Heinze, G., and Pavón, L. (2007). Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 9, 596-602.
107. Pan, Z.K., Zuraw, B.L., Lung, C.C., Prossnitz, E.R., Browning, D.D., and Ye, R.D. (1996). Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J. Clin. Invest. 98, 2042-2049.
108. Parpura, V., Basarsky, T.A., Liu, F., Jeftinija, K., Jeftinija, S., and Haydon, P.G. (1994). Glutamate-mediated astrocyte-neuron signalling. Nature 369, 744-747.
109. Passos, G.F., Fernandes, E.S., Campos, M.M., Araújo, J.G., Pesquero, J.L., Souza, G.E., Avellar, M.C., Teixeira, M.M., and Calixto, J.B. (2004). Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J. Immunol. 172, 1839-1847.
110. Passos, G.F., Medeiros, R., Cheng, D., Vasilevko, V., Laferla, F.M., and Cribbs, D.H. (2013). The bradykinin B1 receptor regulates Aβdeposition and neuroinflammation in Tg-SwDI mice. Am. J. Pathol. 182, 1740-1749.
111. Perlis, R.H. (2007). Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am. J. Manag. Care 13, S178-S188.
112. Perlis, R.H., Ostacher, M.J., Patel, J.K., Marangell, L.B., Zhang, H., Wisniewski, S.R., Ketter, T.A., Miklowitz, D.J., Otto, M.W., Gyulai, L., et al. (2006). Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 163, 217-224.
113. Perosa, S.R., Argañaraz, G.A., Goto, E.M., Costa, L.G., Konno, A.C., Varella, P.P., Santiago, J.F., Pesquero, J.B., Canzian, M., Amado, D., et al. (2007). Kinin B1 and B2 receptors are overexpressed in the hippocampus of humans with temporal lobe epilepsy. Hippocampus 17, 26-33.
114. Pesquero, J.B., Araujo, R.C., Heppenstall, P.A., Stucky, C.L., Silva, J.A. Jr., Walther, T., Oliveira, S.M., Pesquero, J.L., Paiva, A.C., Calixto, J.B., et al. (2000). Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc. Natl. Acad. Sci. USA 97, 8140-8145.
115. Petersein, C., Sack, U., Mergl, R., Schönherr, J., Schmidt, F.M., Lichtblau, N., Kirkby, K.C., Bauer, K., and Himmerich, H. (2015). Impact of lithium alone and in combination with antidepressants on cytokine production in vitro. J. Neural. Transm. 122, 109-122.
116. Phagoo, S.B., Poole, S., and Leeb-Lundberg, L.M. (1999). Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol. Pharmacol. 56, 325-333.
117. Pillat, M.M., Oliveira, M.N., Motaln, H., Breznik, B., Glaser, T., Lah, T.T., and Ulrich, H. (2015). Glioblastoma-mesenchymal stem cell communication modulates expression patterns of kinin receptors: possible involvement of bradykinin in information flow. Cytometry A. DOI: 10.1002/cyto.a.22800 [Epub ahead of print].
118. Post, R.M., Frye, M.A., Denicoff, K.D., Leverich, G.S., Kimbrell, T.A., and Dunn, R.T. (1998). Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 19, 206-219.
119. Prat, A., Weinrib, L., Becher, B., Poirier, J., Duquette, P., Couture, R., and Antel, J.P. (1999). Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology 53, 2087-2092.
120. Prather, A.A., Rabinovitz, M., Pollock, B.G., and Lotrich, F.E. (2009). Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav. Immun. 23, 1109-1116.
121. Prossin, A.R., Zalcman, S.S., Evans, S.J., McInnis, M.G., and Ellingrod, V.L. (2013). A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder. Ther. Drug. Monit. 35, 194-202.
122. Raidoo, D.M. and Bhoola, K.D. (1997). Kinin receptors on human neurones. J. Neuroimmunol. 77, 39-44.
123. Rajkowska, G. (2000). Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry. 48, 766-777.
124. Rajkowska, G., Halaris, A., and Selemon, L.D. (2001). Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry 49, 741-752.
125. Rao, J.S., Harry, G.J., Rapoport, S.I., and Kim, H.W. (2010). Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 15, 384-392.
126. Rege, S. and Hodgkinson, S.J. (2013). Immune dysregulation and autoimmunity in bipolar disorder: synthesis of the evidence and its clinical application. Aust. N. Z. J. Psychiatry 47, 1136-1151.
127. Remlinger-Molenda, A., Wójciak, P., Michalak, M., and Rybakowski, J. (2012). [Activity of selected cytokines in bipolar patients during manic and depressive episodes]. Psychiatr. Pol. 46, 599-611.
128. Réus, G.Z., Fries, G.R., Stertz, L., Badawy, M., Passos, I.C., Barichello, T., Kapczinski, F., and Quevedo, J. (2015). The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300, 141-154.
129. Ritter, P.S., Kretschmer, K., Pfennig, A., and Soltmann, B. (2013). Disturbed sleep in bipolar disorder is related to an elevation of IL-6 in peripheral monocytes. Med. Hypotheses 81, 1031-1033.
130. Salvadore, G., Quiroz, J.A., Machado-Vieira, R., Henter, I.D., Manji, H.K., and Zarate, C.A. (2010a). The neurobiology of the switch process in bipolar disorder: a review. J. Clin. Psychiatry 71, 1488-1501.
131. Salvadore, G., Viale, C.I., Luckenbaugh, D.A., Zanatto, V.C., Portela, L.V., Souza, D.O., Zarate, C.A., and Machado-Vieira, R. (2010b). Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 819-821.
132. Schanstra, J.P., Bataillé, E., Marin Castaño, M.E., Barascud, Y., Hirtz, C., Pesquero, J.B., Pecher, C., Gauthier, F., Girolami, J.P., and Bascands, J.L. (1998). The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-B and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J. Clin. Invest. 101, 2080-2091.
133. Schneider, M.R., Del Bello, M.P., McNamara, R.K., Strakowski, S.M., and Adler, C.M. (2012). Neuroprogression in bipolar disorder. Bipolar Disord. 14, 356-374.
134. Schoenfeld, T.J. and Cameron, H.A. (2015). Adult neurogenesis and mental illness. Neuropsychopharmacology 40, 113-128.
135. Schwaninger, M., Sallmann, S., Petersen, N., Schneider, A., Prinz, S., Libermann, T.A., and Spranger, M. (1999). Bradykinin induces interleukin-6 expression in astrocytes through activation of nuclear factor-kappaB. J. Neurochem. 73, 1461-1466.
136. Schütze, S., Wiegmann, K., Machleidt, T., and Krönke, M. (1995). TNF-induced activation of NF-kappa B. Immunobiology 193, 193-203.
137. Shorter, E. (2009). The history of lithium therapy. Bipolar Disord. 11 (Suppl 2), 4-9.
138. Sklar, P., Gabriel, S.B., McInnis, M.G., Bennett, P., Lim, Y., Tsan, G., Schaffner, S., Kirov, G., Jones, I., Owen, M., et al. (2002). Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol. Psychiatry. 7, 579-593.
139. Söderlund, J., Olsson, S.K., Samuelsson, M., Walther-Jallow, L., Johansson, C., Erhardt, S., Landén, M., and Engberg, G. (2011). Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J. Psychiatr. Neurosci. 36, 114-118.
140. Song, Y.R., Wu, B., Yang, Y.T., Chen, J., Zhang, L.J., Zhang, Z.W., Shi, H.Y., Huang, C.L., Pan, J.X., and Xie, P. (2015). Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorder. Braz. J. Med. Biol. Res. 48, 973-982.
141. Squassina, A., Manchia, M., and Del Zompo, M. (2010). Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Hum. Genomics Proteomics 2010, 159761.
142. Stephens, G.J., Marriott, D.R., Djamgoz, M.B., and Wilkin, G.P. (1993). Electrophysiological and biochemical evidence for bradykinin receptors on cultured rat cortical oligodendrocytes. Neurosci. Lett. 153, 223-226.
143. Stertz, L., Magalhães, P.V., and Kapczinski, F. (2013). Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr. Opin. Psychiatry 26, 19-26.
144. Strakowski, S.M. (2012). The Bipolar Brain: Neuroimaging and Genetics (New York: Oxford University Press, Inc).
145. Strakowski, S.M., DelBello, M.P., Zimmerman, M.E., Getz, G.E., Mills, N.P., Ret, J., Shear, P., and Adler, C.M. (2002). Ventricular and periventricular structural volumes in first-versus multipleepisode bipolar disorder. Am. J. Psychiatry 159, 1841-1847.
146. Thornton, E., Ziebell, J.M., Leonard, A.V., and Vink, R. (2010). Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury. Molecules 15, 6598-6618.
147. Tohen, M., Zarate, C.A., Hennen, J., Khalsa, H.M., Strakowski, S.M., Gebre-Medhin, P., Salvatore, P., and Baldessarini, R.J. (2003). The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am. J. Psychiatry 160, 2099-2107.
148. Trabold, R., Erös, C., Zweckberger, K., Relton, J., Beck, H., Nussberger, J., Müller-Esterl, W., Bader, M., Whalley, E., and Plesnila, N. (2010). The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice. J. Cereb. Blood Flow Metab. 30, 130-139.
149. Trujillo, C.A., Schwindt, T.T., Martins, A.H., Alves, J.M., Mello, L.E., and Ulrich, H. (2009). Novel perspectives of neural stem cell differentiation: from neurotransmitters to therapeutics. Cytometry A 75, 38-53.
150. Trujillo, C.A., Negraes, P.D., Schwindt, T.T., Lameu, C., Carromeu, C., Muotri, A.R., Pesquero, J.B., Cerqueira, D.M., Pillat, M.M., de Souza, H.D., et al. (2012). Kinin-B2 receptor activity determines the differentiation fate of neural stem cells. J. Biol. Chem. 287, 44046-44061.
151. Uhl, J., Singh, S., Brophy, L., Faunce, D., and Sawutz, D.G. (1992). Role of bradykinin in inflammatory arthritis: identification and functional analysis of bradykinin receptors on human synovial fibroblasts. Immunopharmacology 23, 131-138.
152. Uknis, A.B., DeLa Cadena, R.A., Janardham, R., Sartor, R.B., Whalley, E.T., and Colman, R.W. (2001). Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat. Inflamm. Res. 50, 149-155.
153. Viana, A.F., Maciel, I.S., Dornelles, F.N., Figueiredo, C.P., Siqueira, J.M., Campos, M.M., and Calixto, J.B. (2010). Kinin B1 receptors mediate depression-like behavior response in stressed mice treated with systemic E. coli lipopolysaccharide. J. Neuroinflammation 7, 98.
154. Viel, T.A. and Buck, H.S. (2011). Kallikrein-kinin system mediated inflammation in Alzheimer's disease in vivo. Curr. Alzheimer Res. 8, 59-66.
155. Wang, M.J., Huang, H.Y., Chen, W.F., Chang, H.F., and Kuo, J.S. (2010). Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. J. Neuroinflammation 7, 99.
156. Watkins, C.C., Sawa, A., and Pomper, M.G. (2014). Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl. Psychiatry 4, e350.
157. Weitz, T.M. and Town, T. (2012). Microglia in alzheimer's disease: it's all about context. Int. J. Alzheimers Dis. 2012, 314185.
158. Williams, N.M., Green, E.K., Macgregor, S., Dwyer, S., Norton, N., Williams, H., Raybould, R., Grozeva, D., Hamshere, M., Zammit, S., et al. (2006). Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 63, 366-373.
159. Yang, C.M., Tsai, Y.J., Pan, S.L., Wu, W.B., Wang, C.C., Lee, Y.S., Lin, C.C., Huang, S.C., and Chiu, C.T. (1999). Pharmacological and functional characterization of bradykinin receptors in rat cultured vascular smooth muscle cells. Cell Signal 11, 853-862.
160. Yasuyoshi, H., Kashii, S., Zhang, S., Nishida, A., Yamauchi, T., Honda, Y., Asano, Y., Sato, S., and Akaike, A. (2000). Protective effect of bradykinin against glutamate neurotoxicity in cultured rat retinal neurons. Invest. Ophthalmol. Vis. Sci. 41, 2273-2278.
161. Yin, H., Chao, L., and Chao, J. (2005). Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J. Biol. Chem. 280, 8022-8030.
162. Yin, H., Chao, J., Bader, M., and Chao, L. (2007). Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 28, 1383-1389.
163. Yuskaitis, C.J. and Jope, R.S. (2009). Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 21, 264-273.